Now Enrolling Patients with Recurrent Anaplastic Astrocytoma (rAA) Brain Cancer
Complete the form below to see if you or a loved one may qualify.
Are you eligible?
You may be eligible if:
Your doctor has told you that you have anaplastic astrocytoma (AA)
You have already been treated with radiation and a chemotherapy drug called temozolomide (also known as Temodar®)
Your doctor has told you that the tumor has recurred (come back) or has progressed (grown or changed) within the past 6 months
You completed radiation therapy more than 6 months ago
You are an adult over the age of 18 years old
Participants may be eligible for study-related travel reimbursement.
What is the STELLAR study?
Brain cancer experts are conducting the STELLAR study to evaluate the use of eflornithine oral investigational medicine for treating recurrent anaplastic astrocytoma (rAA).
Eflornithine is an investigational product. An investigational product is one that has not been proven to be safe and effective for this use and is not licensed by the US Food and Drug Administration or any other government agency. An investigational product can only be administered in a research study.Participation details
Recruiting participants at selected medical centers in the United States, Belgium, Canada, Germany, Italy, France, United Kingdom and the Netherlands.